Cat#:Y07901
Name:Recombinant Human TGF-β3
Species:Human
Purity:≥95%
Endotoxin: ≤10 EU/mg
Expression System:CHO
Size: 50μg 1mg
Price: $552.00 $3,390.00
Instruction
Cat#:Y07901
Name:Recombinant Human TGF-β3
Species:Human
Purity:≥95%
Endotoxin: ≤10 EU/mg
Expression System:CHO
Size: 50μg 1mg
Price: $552.00 $3,390.00
General description
Transforming Growth Factor Beta 3 (TGF-β3) is a pleiotropic cytokine essential for embryonic development, palatogenesis, and scarless wound healing. It exhibits distinct anti-fibrotic properties compared to TGF-β1. Recombinant Human TGF-β3 Protein (Y07901) is expressed from mammalian cells. It contains AA Ala 301 - Ser 412 (Accession # P10600), and is widely used in advanced cell culture, regenerative medicine, and wound healing research.
Application
· Scarless Wound Healing Research — Models fetal wound healing mechanisms and anti-scarring therapeutics.
· Palatal Fusion Studies — Investigates craniofacial developmental biology and cleft palate pathogenesis.
· Chondrogenic and Osteogenic Differentiation — Directs MSC differentiation for cartilage and bone tissue engineering.
· Fibrosis Antagonism Studies — Explores TGF-β3-mediated suppression of fibrotic responses.
· Serum-Free Culture Systems — Suitable for chemically defined and xeno-free cell culture media.
Product Specifications
Cat. No. | Y07901 |
Purity | ≥95%, by SDS-PAGE (under reducing (R) & Non-reducing conditions, visualized by Coomassie staining). |
Endotoxin | ≤10 EU/mg by the LAL method. |
Bioactivity | Measured in a cell inhibition assay using TF-1 cells at IL4 presence. The ED50 for this effect is ≤0.2 ng/mL. |
Accession | P10600 |
Alternative Names | Transforming growth factor beta-3; TGFB3; TGF-beta-3; Latency-associated peptide; LAP |
Species | Human |
Expression System | CHO |
Mol. Weight | 13 kDa |
Expression Region | Ala 301-Ser 412 |
Tag Info | Tag free |
Formulation | Lyophilized |
Buffer | Lyophilized from a 0.22 μm-filtered solution containing 100 mM Glycine, 150 mM NaCl, 5% Mannitol and 0.01% Tween 80, pH 4.0. |
Lead Time | Products are in stock,but custom products may require further consultation. |
Shipping | The product is shipped with blue ice. |
Stability and Reconstitution
· 36 months at -20°C to -80°C in lyophilized state;
· 6 months at -20°C to -80°C under sterile conditions after reconstitution;
· 7-10 days at 2°C to 8°C under sterile conditions after reconstitution;
· Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
· It is recommended to redissolve in sterile deionized water.
Backgroud
Transforming Growth Factor Beta 3 (TGF-β3), also known as ARVD or RNHF, is a member of the TGF-β superfamily. TGF-β3 is highly expressed during embryonic development, particularly in the developing palate, lung, and kidney. Unlike TGF-β1, which promotes fibrotic scarring, TGF-β3 is associated with scarless wound healing observed in fetal tissues. This distinctive property has generated significant interest in TGF-β3 as a therapeutic candidate for reducing post-surgical adhesions and hypertrophic scarring. TGF-β3 signals through the canonical TGF-β receptor-SMAD pathway but can activate alternative signaling cascades that oppose pro-fibrotic gene expression programs.
Q&A
Q1: What is TGF-β3 mainly used for?
TGF-β3 is primarily used for wound healing research, craniofacial development studies, MSC differentiation, and anti-fibrosis investigations.
Q2: Is this TGF-β3 suitable for serum-free culture systems?
Yes. EastMabBio recombinant TGF-β3 is compatible with serum-free, xeno-free, and chemically defined media systems.
Q3: How should recombinant TGF-β3 be stored?
Lyophilized protein should be stored at -20°C or below. After reconstitution, aliquot and avoid repeated freeze-thaw cycles.
Q4: What shipping conditions are used?
Products are shipped on dry ice with validated cold-chain packaging to maintain stability during international transportation.
Q5: Do you provide QC documents?
Yes. COA, MSDS, TSE-BSE statements, endotoxin reports, bioactivity data, and additional QC documentation are available upon request.
SDS-PAGE

Recombinant Human TGF-β3 (Cat. No. Y07901) SDS-PAGE under reducing (R) & Non-reducing (NR) condition.
Bioactivity

Measured in a cell inhibition assay using TF-1 cells at IL4 presence. The ED50 for this effect is ≤0.2 ng/mL.


SEC-HPLC

Jiangsu East-Mab Bio:Building 13 and 17, 888 Zhujiang Road, Nantong, Jiangsu 226499 , China
Suzhou East-Mab Bio:Floor 5 & 6, Building 1, 168 Majian Road, Suzhou, Jiangsu 215129, China
Platform Information Submission-Privacy Agreement
· Privacy Policy
No content yet
Platform Information Statement-Laws and Regulations
· Laws and regulations
Trademark registration of Jiangsu Dongkang Biomedical Technology Co., Ltd.
East Mab
East Mab Bio
东抗生物
To download COA, please enter the product batch and specification information in the search box.
You can also ask us directly via the following email: dongkang@Sales.com